Depression: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BDNF 1
• NMDA 7
• NLRP3 0
• GLP-1 1
• TNF 0
• IL-6 3
• NRF2 0
• PPAR 0
• AMPK 0
• mTOR 0
• STAT3 0
• AKT 0
• JAK 1
• TLR4 0
• ERK 0
• IL-1 0
• PI3K 0
• AQP4 0
• HDAC 0
• HMGB1 0
• METTL3 0
• MMP-9 0
• SGLT2 0
• SIRT1 0
• VEGF 0
• BACE1 0
• C9orf72 0
• CCR5 0
• CD19 0
• CD22 0
• COX-2 0
• CTNNB1 0
• CXCR4 0
• DPP-4 0
• FOXP3 0
• HSP90 0
• IDO1 0
• IL-15 0
• IL-17 0
• IL-4 1
• MAPK 0
• MEK 0
• PARP 0
• PDGFR 0
• PINK1 0
• PRMT5 0
• RANKL 0
• SNCA 0
• STING 0
• TP53 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis

  NCT06329414· University of Utah· Updated 6 Nov 2026

  “Recruitment Failure”Registry text, quoted unchanged. Source

• Terminated

  Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Updated 5 Nov 2026

  “The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.”Registry text, quoted unchanged. Source

• Withdrawn

  Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day

  NCT03986658· NeuroQore Inc.· Updated 2 Nov 2026

  “Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.”Registry text, quoted unchanged. Source

• Withdrawn

  Ketamine Biomarker Validation

  NCT07307768· Soterix Medical· Updated 19 Oct 2026

  “Funding was not provided”Registry text, quoted unchanged. Source

• Suspended

  Intermittent Theta Burst Stimulation for MDD

  NCT02506127· University of California, Los Angeles· Updated 16 Oct 2026

  “Protocol discontinued for futility”Registry text, quoted unchanged. Source

• Terminated

  Network Analysis of Adult MDD and ADHD

  NCT04504474· Health Sciences North Research Institute· Updated 5 Oct 2026

  “The Health Sciences North Research Ethics Board (HSN REB) has recommended termination of approval for the research project, because it has surpassed the stated date of expiry for renewal.”Registry text, quoted unchanged. Source

• Terminated

  Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)

  NCT06979154· University of North Carolina, Chapel Hill· Updated 28 Sept 2026

  “Due to lack of resources the study was terminated.”Registry text, quoted unchanged. Source

• Suspended

  An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

  NCT07329673· Qbtech AB· Updated 25 Sept 2026

  “Enrollment/study activities have been temporarily suspended while the sponsor evaluates internal study priorities and resource allocation. The suspension is not related to participant safety, protocol compliance, data quality, or regulatory concerns.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements

  NCT07294924· Kernel· Updated 10 Sept 2026

  “Terminated due to low enrollment.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics

  NCT05877885· AdventHealth· Source

• XEN1101 for Major Depressive Disorder

  NCT04827901· James Murrough· Source

• Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences

  NCT07921446· Institute of Mental Health, Singapore· Source

• Biomarker-Guided Antidepressant Selection

  NCT07680140· Weill Medical College of Cornell University· Source

• Digital Interventions for Relapse Prevention in Adolescence

  NCT07346911· University of Oslo· Source

• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Source

• Neural Circuit Effects of Ketamine in Depression

  NCT06213324· Icahn School of Medicine at Mount Sinai· Source

• A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Eli Lilly and Company· Source

• A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Eli Lilly and Company· Source

• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  NCT07573176· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 14
• Mendelian Randomization Analysis 82
• CRISPR-Cas Systems 1
• Gene Expression Profiling 60
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 1
• Exome Sequencing 4
• Proteomics 25
• Metabolomics 21
• Mass Spectrometry 2
• Flow Cytometry 1
• Immunohistochemistry 1
• Positron-Emission Tomography 25
• Magnetic Resonance Imaging 453
• Machine Learning 106
• Deep Learning 20
• Cohort Studies 125
• Genome-Wide Association Study 147

• Shared genetic architecture and pathways linking major depressive disorder and autoimmune thyroid disease: insights from common and rare variants.

  Transl Psychiatry, Jun 2026

• Genotype-stratified Default Mode Network hyperconnectivity in major depressive disorder: an MR imaging genetics study.

  J Affect Disord, Apr 2026

• Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations.

  Clin Pharmacol Ther, Jan 2026

• Measuring the health benefits of genome and exome sequencing: a systematic review of economic evaluations.

  Front Public Health, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.